Synapse - Howard Scher

Results (1133)

A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)

Meeting Abstract

Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study

Meeting Abstract

Logothetis, C.; De Bono, J. S.; Molina, A.; Basch, E. M.; Fizazi, K.; North, S. A.; Chi, K. N.; Jones, R. J.; Goodman, O. B.; Mainwaring, P. N.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Initial study of bone scan tumor area for early surrogate outcome assessment in patients with metastatic castration-resistant prostate cancer

Meeting Abstract

Kim, H. J.; Brown, M. S.; Chu, G. H.; Gjertson, D. W.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Morris, M. J.; Larson, S. M.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload

Meeting Abstract

Dennis, E. R.; Fox, J. J.; Larson, S. M.; Farrelly, J. S.; Schwartz, L. H.; Schöder, H.; Haupt, E. C.; Borwick, L. S.; Scher, H. I.; Morris, M. J.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D)

Meeting Abstract

Drake, C. G.; Scher, H. I.; Gerritsen, W. R.; Ezzeddine, R.; Fitzmaurice, T. F.; Cuillerot, J.; Chin, K. M.; Gagnier, P.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Genomic analysis of circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) as predictive biomarkers

Meeting Abstract

Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Initial analytic validation of automated bone scan measures for treatment response assessment in patients with metastatic castration-resistant prostate cancer (CRPC)

Meeting Abstract

Chu, G. H.; Brown, M. S.; Kim, H. J.; Auerbach, M.; Poon, C.; Ramakrishna, B.; Vidovic, A.; Gjertson, D. W.; Morris, M. J.; Larson, S. M.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Automated tumor detection on bone scans for treatment response assessment

Meeting Abstract

Brown, M. S.; Chu, G. H.; Kim, H. J.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Gjertson, D. W.; Morris, M. J.; Larson, S. M.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC)

Meeting Abstract

Baklajian, A.; Dennis, E. R.; Buddle, J. R.; Fox, J. J.; Schoder, H.; Morris, M. J.; Larson, S. M.; Scher, H. I.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy

Meeting Abstract

Scher, H. I.; Logothetis, C.; Molina, A.; Goodman, O. B.; Sternberg, C. N.; Chi, K. N.; Kheoh, T. S.; Haqq, C. M.; Fizazi, K.; De Bono, J. S.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save